UNSPSC 51263168: Metoprolol succinate

This classification denotes a beta-adrenergic blocking agent with the molecular formula 2C15H25NO3.C4H6O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TH25PD4CCB, chemically known as 2-propanol, 1-(4-(2-methoxyethyl)phenoxy)-3-((1-methylethyl)amino)-, (+-)-, butanedioate (2:1) (salt) but more generally known as metoprolol succinate, which bears US NIH Compound Identifier 62937. European Medicines Agency schedules Metoprolol succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03274MIG.

UNSPSC 51263168 Metoprolol succinate is a Commodity code that nominally describes a beta-blocker pharmaceutical product, but recent state and local solicitations tagged under this code show minimal activity directly aligned with the drug itself. The most recent opportunity actually solicits naloxone and drug deactivation systems—products entirely unrelated to metoprolol succinate—suggesting either a coding error in the state or local procurement system or a mismatch between the code assignment and actual procurement scope. A second opportunity from Texas HHS represents a Request for Information regarding direct-to-manufacturer prescription programs with no specific drug or product named. State and local governments do procure pharmaceuticals and medical supplies through competitive bidding, but this code's recent activity does not reflect a coherent buying pattern for metoprolol succinate or a clear pharmaceutical acquisition strategy.

The geographic spread of recent activity is narrow: Seminole County, Florida issued an IFB for naloxone and deactivation systems (due July 26, 2023), and Texas Health and Human Services Commission issued an RFI on direct-to-manufacturer prescriptions (due April 3, 2026). No other state or local jurisdictions appear in the recent-opportunities block. Given the mismatch between the code's pharmaceutical name and the actual products being solicited, and the sparse activity overall, this code shows little relevant recent procurement activity for business development purposes. Firms pursuing pharmaceutical supply contracts with state and local governments should monitor codes aligned with their actual product lines rather than rely on this code's current activity signals.